Showing results (11-20 of 47) with videos related to
Sort By:
Pageof 5
Expert Review of Hematology|July 22, 2024
How can we optimize antifungal use and stewardship in the treatment of acute leukemia?Thomas Taynton, David Allsup, Gavin BarlowLeukemia & Lymphoma|June 21, 2026
An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysisStefano Molica, Diana Giannarelli, David AllsupFrontiers in Oncology|April 24, 2023
An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapiesSujoy Khan, David Allsup, Stefano MolicaCancers|July 29, 2023
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic OptionStefano Molica, Constantine Tam, David Allsup, et al.Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|May 16, 2013
The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkersElena Kashuba, James Bailey, David Allsup, et al.Leukemia & Lymphoma|December 5, 2008
Protein-tyrosine phosphatase activity maintains the viability of hairy cells and modulates their response to interferon-alphaDavid Allsup, Robert Harris, Peter Baker, et al.Hematological Oncology|November 8, 2023
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directionsStefano Molica, Constantine Tam, David Allsup, et al.Case Reports in Hematology|November 25, 2024
High-Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib-Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase InhibitionDaniel James, Simone Green, Stefano Molica, et al.Cancers|March 28, 2024
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched PopulationStefano Molica, Tait D Shanafelt, David Allsup, et al.American Journal of Hematology|December 15, 2023
Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched populationStefano Molica, Tait D Shanafelt, David Allsup, et al.Pageof 5